Stay updated with breaking news from Dose Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
REDWOOD CITY - Biomea Fusion, Inc. , a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with...
Initial topline data from COVALENT-101 trial revealed 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose Level 4 exposure...
Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
NEW YORK, June 09, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated... | June 9, 2023